Kura Oncology KURA KOMZIFTI — Royalty Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The official record: Kura Oncology’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's komzifti — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's KOMZIFTI — royalty expense?
- Kura Oncology (KURA) reported KOMZIFTI — royalty expense of $25K in Q4 2025.
- What does KOMZIFTI — royalty expense mean?
- This metric represents the total costs incurred by the company for royalty payments associated with the commercialization or development of the specified product segment. These expenses typically arise from licensing agreements or intellectual property rights held by third parties that are triggered by product sales or development milestones. Monitoring this figure is essential for assessing the impact of external technology dependencies on the overall gross margin and profitability of the product line.